#BEGIN_DRUGCARD DB01077

# AHFS_Codes:
92:00.00

# ATC_Codes:
M05BA01
M05BB01

# Absorption:
The amount of drug absorbed after an oral dose is approximately 3%.

# Biotransformation:
Not metabolized.

# Brand_Mixtures:
Didrocal (Etidronate Disodium + Calcium Carbonate)

# Brand_Names:
Cintichem Technetium 99m Hedspa
Dequest 2010
Dequest 2015
Dequest Z 010
Didronel
Didronel IV
Ferrofos 510
MPI Stannous Diphosphonate
Osteoscan
Turpinal SL

# CAS_Registry_Number:
7414-83-7

# ChEBI_ID:
4907

# Chemical_Formula:
C2H8O7P2

# Chemical_IUPAC_Name:
(1-hydroxy-1-phosphonoethyl)phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2248686

# Description:
A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [PubChem]

# Dosage_Forms:
Tablet	Oral
Tablet	Oral

# Drug_Category:
Antihypocalcemic Agents
Antineoplastic Agents
Bisphosphonates
Bone Density Conservation Agents
Osteoporosis Prophylactic

# Drug_Interactions:
Aluminium	Formation of non-absorbable complexes
Calcium	Formation of non-absorbable complexes
Calcium Acetate	Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Calcium Chloride	Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate.
Iron	Formation of non-absorbable complexes
Iron Dextran	Formation of non-absorbable complexes
Magnesium	Formation of non-absorbable complexes
Magnesium oxide	Formation of non-absorbable complexes
Sucralfate	Formation of non-absorbable complexes

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Avoid aluminium, calcium, iron and magnesium within 2 hours of taking medication.
Take on an empty stomach with a full glass of water.

# GenBank_ID:
Not Available

# Generic_Name:
Etidronic acid

# HET_ID:
Not Available

# Half_Life:
In normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.

# InChI_Identifier:
InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)

# InChI_Key:
InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N

# Indication:
For the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.

# KEGG_Compound_ID:
C07736

# KEGG_Drug_ID:
D00314

# LIMS_Drug_ID:
1077

# Mechanism_Of_Action:
Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid does not interfere with bone mineralization. In malignancy-related hypercalcemia, etidronic acid decreases serum calcium by inhibiting tumour-induced bone resorption and reducing calcium flow from the resorbing bone into the blood. Etidronic acid also reduces morbidity of osteolytic bone metastases by inhibiting tumour-induced bone resorption. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
206.0282

# Molecular_Weight_Mono:
205.974525634

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449548

# Pharmacology:
Etidronic acid is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronic acid affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronic acid that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronic acid has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.

# Predicted_LogP_Hydrophobicity:
-0.77

# Predicted_LogS:
-1.2

# Predicted_Water_Solubility:
1.15e+01 g/l

# Primary_Accession_No:
DB01077

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3305

# PubChem_Substance_ID:
46507694

# RxList_Link:
http://www.rxlist.com/cgi/generic/didronel.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00964

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(O)(P(O)(O)=O)P(O)(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Acetodiphosphonic acid
Acide etidronique [INN-French]
Acido etidronico [INN-Spanish]
Acidum etidronicum [INN-Latin]
EHDP
Etidronate
Etidronate Disodium
Etidronsaeure
HEDP
Hydroxyethanediphosphonic acid
Oxyethylidenediphosphonic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Clinical experience with acute etidronic acid overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.

# Update_Date:
2013-02-08 16:19:53 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Etidronic_acid

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15577056	Ono K, Wada S: [Regulation of calcification by bisphosphonates] Clin Calcium. 2004 Jun;14(6):60-3.
15775080	Takaishi Y: [Treatment of periodontal disease, prevention and bisphosphonate] Clin Calcium. 2003 Feb;13(2):173-6.
16046206	Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20.
17587727	Grases F, Sanchis P, Perello J, Isern B, Prieto RM, Fernandez-Palomeque C, Torres JJ: Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats. Circ J. 2007 Jul;71(7):1152-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Hydroxylapatite is the main mineral component of bone. Carbonated-calcium deficient hydroxyapatite is the main mineral of which dental enamel and dentin are comprised.

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
930

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
502.311

# Drug_Target_1_Name:
Hydroxyapatite

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
1

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
8610169	Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U35234

# Drug_Target_2_GenBank_ID_Protein:
1109792

# Drug_Target_2_GeneCard_ID:
PTPRS

# Drug_Target_2_Gene_Name:
PTPRS

# Drug_Target_2_Gene_Sequence:
>5847 bp
ATGGCGCCCACCTGGGGCCCTGGCATGGTGTCTGTGGTTGGTCCCATGGGCCTCCTTGTG
GTCCTGCTCGTTGGAGGCTGTGCAGCAGAAGAGCCCCCCAGGTTTATCAAAGAACCCAAG
GACCAGATCGGCGTGTCGGGGGGTGTGGCCTCTTTCGTGTGTCAGGCCACGGGTGACCCC
AAGCCACGAGTGACCTGGAACAAGAAGGGCAAGAAGGTCAACTCTCAGCGCTTTGAGACG
ATTGAGTTTGATGAGAGTGCCGGGGCAGTGCTGAGGATCCAGCCGCTGAGGACACCGCGG
GATGAAAACGTGTACGAGTGTGTGGCCCAGAACTCGGTTGGGGAGATCACAGTCCATGCC
AAGCTTACTGTCCTCCGAGAGGACCAGCTGCCCTCTGGCTTCCCCAACATCGACATGGGC
CCACAGTTGAAGGTGGTGGAGCGGACACGGACAGCCACCATGCTCTGTGCAGCCAGCGGC
AACCCTGACCCTGAGATCACCTGGTTCAAGGACTTCCTGCCTGTGGATCCTAGTGCCAGC
AATGGACGCATCAAACAGCTGCGATCAGAAACCTTTGAAAGCACTCCGATTCGAGGAGCC
CTGCAGATTGAAAGCAGTGAGGAAACCGACCAGGGCAAATATGAGTGTGTGGCCACCAAC
AGCGCCGGCGTGCGCTACTCCTCACCTGCCAACCTCTACGTGCGAGAGCTTCGAGAAGTC
CGCCGCGTGGCCCCGCGCTTCTCCATCCTGCCCATGAGCCACGAGATCATGCCAGGGGGC
AACGTGAACATCACCTGCGTGGCCGTGGGCTCGCCCATGCCATACGTGAAGTGGATGCAG
GGGGCCGAGGACCTGACCCCCGAGGATGACATGCCCGTGGGTCGGAACGTGCTGGAACTC
ACAGATGTCAAGGACTCGGCCAACTACACCTGCGTGGCCATGTCCAGCCTGGGCGTCATT
GAGGCGGTTGCTCAGATCACGGTGAAATCTCTCCCCAAAGCTCCCGGGACTCCCATGGTG
ACTGAGAACACAGCCACCAGCATCACCATCACGTGGGACTCGGGCAACCCAGATCCTGTG
TCCTATTACGTCATCGAATATAAATCCAAGAGCCAAGACGGGCCGTATCAGATTAAAGAG
GACATCACCACCACACGTTACAGCATCGGCGGCCTGAGCCCCAACTCGGAGTACGAGATC
TGGGTGTCGGCCGTCAACTCCATCGGCCAGGGGCCCCCCAGCGAGTCCGTGGTCACCCGC
ACAGGCGAGCAGGCCCCGGCCAGCGCGCCGCGGAACGTGCAAGCCCGGATGCTCAGCGCG
ACCACCATGATTGTGCAGTGGGAGGAGCCGGTGGAGCCCAACGGCCTGATCCGCGGCTAC
CGCGTCTACTACACCATGGAACCGGAGCACCCCGTGGGCAACTGGCAGAAGCACAACGTG
GACGACAGCCTGCTGACCACCGTGGGCAGCCTGCTGGAGGACGAGACCTACACCGTGCGG
GTGCTCGCCTTCACCTCCGTCGGCGACGGGCCCCTCTCGGACCCCATCCAGGTCAAGACG
CAGCAGGGAGTGCCGGGCCAGCCCATGAACCTGCGGGCCGAGGCCAGGTCGGAGACCAGC
ATCACGCTGTCCTGGAGCCCCCCGCGGCAGGAGAGTATCATCAAGTACGAGCTCCTCTTC
CGGGAAGGCGACCATGGCCGGGAGGTGGGAAGGACCTTCGACCCGACGACTTCCTACGTG
GTGGAGGACCTGAAGCCCAACACGGAGTACGCCTTCCGCCTGGCCGCCCGCTCGCCGCAG
GGCCTGGGCGCCTTCACCCCCGTGGTGCGGCAGCGCACGCTGCAGTCCAAACCGTCAGCC
CCCCCTCAAGACGTTAAATGTGTCAGCGTGCGCTCCACGGCCATTTTGGTAAGTTGGCGC
CCGCCGCCGCCGGAAACGCACAACGGGGCCCTGGTGGGCTACAGCGTCCGCTACCGACCG
CTGGGCTCAGAGGACCCGGAACCCAAGGAGGTGAACGGCATCCCCCCGACCACCACTCAG
ATCCTGCTGGAGGCCTTGGAGAAGTGGACCCAGTACCGCATCACGACTGTCGCTCACACA
GAGGTGGGACCAGGGCCCGAGAGCTCACCCGTGGTCGTCCGCACCGACGAGGATGTGCCC
AGCGCGCCGCCGCGGAAGGTGGAGGCGGAGGCGCTCAACGCCACGGCCATCCGCGTGCTG
TGGCTCGGCCCTGTGCCCGGCCGGCAGCACGGCCAGATCCGCGGCTACCAGGTCCACTAC
GTGCGCATGGAGGGCGCCGAGGGCCGCGGGCCGCCGCGCATCAAGGACGTCATGCTGGCC
GATGCCCAGTGGGAGACGGATGACACGGCCGAATATGAGATGGTCATCACAAACTTGCAG
CCTGAGACCGCGTACTCCATCACGGTAGCCGCCTACACCATGAAGGGCGATGGCGCTCGC
AGCAAACCCAAGGTGGTTGTGACCAAGGGAGCAGTGTTGGGCCGCCCAACCCTGTCGGTG
CAGCAGACCCCCGAGGGCAGCCTGCTGGCACGCTGGGAGCCCCCGGCTGGCACCGCGGAG
GACCAGGTGCTGGGCTACCGCCTGCAGTTTGGCCGTGAGGACTCGACGCCCCTGGCCACC
CTGGAGTTCCCGCCCTCCGAGGACCGCTACACGGCATCAGGCGTGCACAAGGGGGCCACG
TATGTGTTCCGGCTTGCGGCCCGGAGCCGGGGCGGCCTGGGCGAGGAGGCAGCCGAGGTC
CTGAGCATCCCGGAGGACACGCCCCGTGGCCACCCGCAGATTTTGGAAGCCGCCGGCAAC
GCCTCGGCCGGGACCGTCCTTCTCCGCTGGCTGCCACCCGTGCCCGCCGAGCGCAACGGG
GCCATCGTCAAATACACGGTGGCCGTGCGTGAGGCCGGTGCCCTGGGCCCTGCCCGAGAG
ACTGAGCTGCCGGCAGCGGCTGAGCCGGGCGCGGAGAACGCCGTCACGCTGCAGGGCCTG
AAGCCCGACACGGCCTATGACCTCCAAGTGCGAGCCCACACGCGCCGGGGCCCTGGCCCC
TTCAGCCCCCCCGTCCGCTACCGGACGTTCCTGCGGGACCAAGTCTCGCCCAAGAACTTC
AAGGTGAAAATGATCATGAAGACATCAGTTCTGCTCAGCTGGGAGTTCCCTGACAACTAC
AACTCACCCACACCCTACAAGATCCAGTACAATGGGCTCACACTGGATGTGGATGGCCGT
ACCACCAAGAAGCTCATCACGCACCTCAAGCCCCACACCTTCTACAACTTTGTGCTGACC
AATCGCGGCAGCAGCCTGGGCGGCCTCCAGCAGACGGTCACCGCCTGGACTGCCTTCAAC
CTGCTCAACGGCAAGCCCAGCGTCGCCCCCAAGCCTGATGCTGACGGCTTCATCATGGTG
TATCTTCCTGACGGCCAGAGCCCCGTGCCTGTCCAGAGCTATTTCATTGTGATGGTGCCA
CTGCGCAAGTCTCGTGGAGGCCAATTCCTGACCCCGCTGGGTAGCCCAGAGGACATGGAT
CTGGAAGAGCTCATCCAGGACATCTCACGGCTACAGAGGCGCACCGTGCGGCACTCGCGT
CAGCTGGAGGTGCCCCGGCCCTATATTGCAGCTCGCTTCTCTGTGCTGCCACCCACGTTC
CATCCCGGCGACCAGAAGCAGTATGGCGGCTTCGATAACCGGGGCCTGGAGCCCGGCCAC
CGCTATGTCCTCTTCGTGCTTGCCGTGCTTCAGAAGAGCGAGCCTACCTTTGCAGCCAGT
CCCTTCTCAGACCCCTTCCAGCTGGATAACCCGGACCCCCAGCCCATCGTGGATGGCGAG
GAGGGGCTTATCTGGGTGATCGGGCCTGTGCTGGCCGTGGTCTTCATAATCTGCATTGTC
ATTGCTATCCTGCTCTACAAGAACAAACCCGACAGTAAACGCAAGGACTCAGAACCCCGC
ACCAAATGCCTCCTGAACAATGCCGACCTCGCCCCTCACCACCCCAAGGACCCTGTGGAA
ATGAGACGCATTAACTTCCAGACTCCAGATTCAGGCCTCAGGAGCCCCCTCAGGGAGCCG
GGGTTTCACTTTGAAAGCATGCTTAGCCACCCGCCAATTCCCATCGCAGACATGGCGGAG
CACACGGAGCGGCTCAAGGCCAACGACAGCCTCAAGCTCTCCCAGGAGTATGAGTCCATC
GACCCTGGACAGCAGTTCACATGGGAACATTCCAACCTGGAAGTGAACAAGCCGAAGAAC
CGCTATGCCAACGTCATCGCCTATGACCACTTCCGTGTCATCCTCCAGCCCATTGAAGGC
ATCATGGGCAGTGATTACATCAATGCCAACTATGTGGACGGCTACCGGCGTCAGAACGCG
TACATTGCCACGCAGGGGCCGCTGCCTGAGACCTTTGGGGACTTCTGGCGTATGGTGTGG
GAGCAGCGGTCGGCGACCATCGTCATGATGACGCGGCTGGAGGAGAAGTCACGGATCAAG
TGTGATCAGTATTGGCCCAACAGAGGCACGGAGACCTACGGCTTCATCCAGGTCACGTTG
CTAGATACCATCGAGCTGGCCACATTCTGCGTCAGGACATTCTCTCTGCACAAGAATGGC
TCCAGTGAGAAACGCGAGGTCCGCCAGTTCCAGTTTACGGCGTGGCCGGACCATGGCGTG
CCCGAATACCCAACGCCCTTCCTGGCTTTCCTGCGGAGAGTCAAGACCTGCAACCCGCCA
GATGCCGGCCCCATCGTGGTTCACTGCAGTGCCGGTGTGGGCCGCACAGGCTGCTTTATC
GTCATCGACGCCATGCTTGAGCGGATCAAGCCAGAGAAGACAGTCGATGTCTATGGCCAC
GTGACGCTCATGAGGTCCCAGCGCAACTACATGGTGCAGACGGAGGACCAGTACAGCTTC
ATCCACGAGGCCCTGCTGGAGGCCGTGGGCTGTGGCAACACAGAAGTGCCCGCACGCAGC
CTCTATGCCTACATCCAGAAGCTGGCCCAGGTGGAGCCTGGCGAACACGTCACTGGCATG
GAACTCGAGTTCAAGCGGCTGGCTAACTCCAAGGCCCACACGTCACGCTTCATCAGTGCC
AATCTGCCTTGTAACAAGTTCAAGAACCGCCTGGTGAACATCATGCCCTATGAGAGCACA
CGGGTCTGTCTGCAACCCATCCGGGGTGTGGAGGGCTCTGACTACATCAACGCCAGCTTC
ATTGATGGCTATAGGCAGCAGAAGGCCTACATCGCGACACAGGGGCCGCTGGCGGAGACC
ACGGAAGACTTCTGGCGCATGCTGTGGGAGAACAATTCGACGATCGTGGTGATGCTGACC
AAGCTGCGGGAGATGGGCCGGGAGAAGTGTCACCAGTACTGGCCGGCCGAGCGCTCTGCC
CGCTACCAGTACTTTGTGGTAGATCCGATGGCAGAATACAACATGCCTCAGTATATCCTG
CGAGAGTTCAAGGTCACAGATGCCCGGGATGGCCAGTCCCGGACTGTCCGGCAGTTCCAG
TTCACAGACTGGCCGGAACAGGGTGTGCCAAAGTCGGGGGAGGGCTTCATCGACTTCATT
GGCCAAGTGCATAAGACTAAGGAGCAGTTTGGCCAGGACGGCCCCATCTCTGTCCACTGC
AGTGCCGGCGTGGGCAGGACGGGCGTCTTCATCACGCTTAGCATCGTGCTGGAGCGGATG
CGGTATGAAGGCGTGGTGGACATCTTTCAGACGGTGAAGATGCTACGAACCCAGCGGCCG
GCCATGGTGCAGACAGAGGATGAGTACCAGTTCTGTTACCAGGCGGCACTGGAGTACCTC
GGAAGCTTTGACCACTATGCAACCTAA

# Drug_Target_2_General_Function:
Involved in protein binding

# Drug_Target_2_General_References:
1370651	Adachi M, Sekiya M, Arimura Y, Takekawa M, Itoh F, Hinoda Y, Imai K, Yachi A: Protein-tyrosine phosphatase expression in pre-B cell NALM-6. Cancer Res. 1992 Feb 1;52(3):737-40.
15057824	Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U, Goodstein D, Couronne O, Tran-Gyamfi M, Aerts A, Altherr M, Ashworth L, Bajorek E, Black S, Branscomb E, Caenepeel S, Carrano A, Caoile C, Chan YM, Christensen M, Cleland CA, Copeland A, Dalin E, Dehal P, Denys M, Detter JC, Escobar J, Flowers D, Fotopulos D, Garcia C, Georgescu AM, Glavina T, Gomez M, Gonzales E, Groza M, Hammon N, Hawkins T, Haydu L, Ho I, Huang W, Israni S, Jett J, Kadner K, Kimball H, Kobayashi A, Larionov V, Leem SH, Lopez F, Lou Y, Lowry S, Malfatti S, Martinez D, McCready P, Medina C, Morgan J, Nelson K, Nolan M, Ovcharenko I, Pitluck S, Pollard M, Popkie AP, Predki P, Quan G, Ramirez L, Rash S, Retterer J, Rodriguez A, Rogers S, Salamov A, Salazar A, She X, Smith D, Slezak T, Solovyev V, Thayer N, Tice H, Tsai M, Ustaszewska A, Vo N, Wagner M, Wheeler J, Wu K, Xie G, Yang J, Dubchak I, Furey TS, DeJong P, Dickson M, Gordon D, Eichler EE, Pennacchio LA, Richardson P, Stubbs L, Rokhsar DS, Myers RM, Rubin EM, Lucas SM: The DNA sequence and biology of human chromosome 19. Nature. 2004 Apr 1;428(6982):529-35.
16335952	Liu T, Qian WJ, Gritsenko MA, Camp DG 2nd, Monroe ME, Moore RJ, Smith RD: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res. 2005 Nov-Dec;4(6):2070-80.
16959974	Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.
19159218	Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res. 2009 Feb;8(2):651-61.
19349973	Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, Schiess R, Aebersold R, Watts JD: Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol. 2009 Apr;27(4):378-86. Epub 2009 Apr 6.
8524829	Pulido R, Serra-Pages C, Tang M, Streuli M: The LAR/PTP delta/PTP sigma subfamily of transmembrane protein-tyrosine-phosphatases: multiple human LAR, PTP delta, and PTP sigma isoforms are expressed in a tissue-specific manner and associate with the LAR-interacting protein LIP.1. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11686-90.
8992885	Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A: Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43.
9624153	Serra-Pages C, Medley QG, Tang M, Hart A, Streuli M: Liprins, a family of LAR transmembrane protein-tyrosine phosphatase-interacting proteins. J Biol Chem. 1998 Jun 19;273(25):15611-20.

# Drug_Target_2_HGNC_ID:
GNC:9681

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6055

# Drug_Target_2_Locus:
19p13.3

# Drug_Target_2_Molecular_Weight:
217092.9

# Drug_Target_2_Name:
Receptor-type tyrosine-protein phosphatase S

# Drug_Target_2_Number_of_Residues:
1948

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00041	fn3
PF00047	ig
PF00102	Y_phosphatase
PF07679	I-set

# Drug_Target_2_Protein_Sequence:
>Receptor-type tyrosine-protein phosphatase S
MAPTWGPGMVSVVGPMGLLVVLLVGGCAAEEPPRFIKEPKDQIGVSGGVASFVCQATGDP
KPRVTWNKKGKKVNSQRFETIEFDESAGAVLRIQPLRTPRDENVYECVAQNSVGEITVHA
KLTVLREDQLPSGFPNIDMGPQLKVVERTRTATMLCAASGNPDPEITWFKDFLPVDPSAS
NGRIKQLRSETFESTPIRGALQIESSEETDQGKYECVATNSAGVRYSSPANLYVRELREV
RRVAPRFSILPMSHEIMPGGNVNITCVAVGSPMPYVKWMQGAEDLTPEDDMPVGRNVLEL
TDVKDSANYTCVAMSSLGVIEAVAQITVKSLPKAPGTPMVTENTATSITITWDSGNPDPV
SYYVIEYKSKSQDGPYQIKEDITTTRYSIGGLSPNSEYEIWVSAVNSIGQGPPSESVVTR
TGEQAPASAPRNVQARMLSATTMIVQWEEPVEPNGLIRGYRVYYTMEPEHPVGNWQKHNV
DDSLLTTVGSLLEDETYTVRVLAFTSVGDGPLSDPIQVKTQQGVPGQPMNLRAEARSETS
ITLSWSPPRQESIIKYELLFREGDHGREVGRTFDPTTSYVVEDLKPNTEYAFRLAARSPQ
GLGAFTPVVRQRTLQSKPSAPPQDVKCVSVRSTAILVSWRPPPPETHNGALVGYSVRYRP
LGSEDPEPKEVNGIPPTTTQILLEALEKWTQYRITTVAHTEVGPGPESSPVVVRTDEDVP
SAPPRKVEAEALNATAIRVLWRSPAPGRQHGQIRGYQVHYVRMEGAEARGPPRIKDVMLA
DAQWETDDTAEYEMVITNLQPETAYSITVAAYTMKGDGARSKPKVVVTKGAVLGRPTLSV
QQTPEGSLLARWEPPAGTAEDQVLGYRLQFGREDSTPLATLEFPPSEDRYTASGVHKGAT
YVFRLAARSRGGLGEEAAEVLSIPEDTPRGHPQILEAAGNASAGTVLLRWLPPVPAERNG
AIVKYTVAVREAGALGPARETELPAAAEPGAENALTLQGLKPDTAYDLQVRAHTRRGPGP
FSPPVRYRTFLRDQVSPKNFKVKMIMKTSVLLSWEFPDNYNSPTPYKIQYNGLTLDVDGR
TTKKLITHLKPHTFYNFVLTNRGSSLGGLQQTVTAWTAFNLLNGKPSVAPKPDADGFIMV
YLPDGQSPVPVQSYFIVMVPLRKSRGGQFLTPLGSPEDMDLEELIQDISRLQRRSLRHSR
QLEVPRPYIAARFSVLPPTFHPGDQKQYGGFDNRGLEPGHRYVLFVLAVLQKSEPTFAAS
PFSDPFQLDNPDPQPIVDGEEGLIWVIGPVLAVVFIICIVIAILLYKNKPDSKRKDSEPR
TKCLLNNADLAPHHPKDPVEMRRINFQTPDSGLRSPLREPGFHFESMLSHPPIPIADMAE
HTERLKANDSLKLSQEYESIDPGQQFTWEHSNLEVNKPKNRYANVIAYDHSRVILQPIEG
IMGSDYINANYVDGYRRQNAYIATQGPLPETFGDFWRMVWEQRSATIVMMTRLEEKSRIK
CDQYWPNRGTETYGFIQVTLLDTIELATFCVRTFSLHKNGSSEKREVRQFQFTAWPDHGV
PEYPTPFLAFLRRVKTCNPPDAGPIVVHCSAGVGRTGCFIVIDAMLERIKPEKTVDVYGH
VTLMRSQRNYMVQTEDQYSFIHEALLEAVGCGNTEVPARSLYAYIQKLAQVEPGEHVTGM
ELEFKRLANSKAHTSRFISANLPCNKFKNRLVNIMPYESTRVCLQPIRGVEGSDYINASF
IDGYRQQKAYIATQGPLAETTEDFWRMLWENNSTIVVMLTKLREMGREKCHQYWPAERSA
RYQYFVVDPMAEYNMPQYILREFKVTDARDGQSRTVRQFQFTDWPEQGVPKSGEGFIDFI
GQVHKTKEQFGQDGPISVHCSAGVGRTGVFITLSIVLERMRYEGVVDIFQTVKMLRTQRP
AMVQTEDEYQFCYQAALEYLGSFDHYAT

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-29

# Drug_Target_2_Specific_Function:
Interacts with LAR-interacting protein LIP.1

# Drug_Target_2_SwissProt_ID:
Q13332

# Drug_Target_2_SwissProt_Name:
PTPRS_HUMAN

# Drug_Target_2_Synonyms:
R-PTP-S
R-PTP-sigma
Receptor-type tyrosine-protein phosphatase sigma

# Drug_Target_2_Theoretical_pI:
6.46

# Drug_Target_2_Transmembrane_Regions:
1283-1303

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
3

# Drug_Target_3_Drug_References:
8889850	David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996 Oct;11(10):1498-507.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L09235

# Drug_Target_3_GenBank_ID_Protein:
291868

# Drug_Target_3_GeneCard_ID:
ATP6V1A

# Drug_Target_3_Gene_Name:
ATP6V1A

# Drug_Target_3_Gene_Sequence:
>1854 bp
ATGGATTTTTCCAAGCTACCCAAAATACTCGATGAAGATAAAGAAAGCACATTTGGTTAT
GTGCATGGGGTCTCAGGACCTGTGGTTACAGCCTGTGACATGGCGGGTGCAGCCATGTAT
GAGCTGGTGAGAGTGGGCCACAGCGAATTGGTTGGAGAGATTATTCGATTGGAGGGTGAC
ATGGCTACTATTCAGGTGTATGAAGAAACTTGTGGTGTGTCTGTTGGAGATCCTGTACTT
CGCACTGGTAAACCCCTCTCTGTAGACGTTGGTCCTGGCATTATGGGAGCCATTTTTGAT
GGTATTCAAAGACCTTTGTCGGATATCAGCAGTCAGACCCAAAGCATCTACATCCCCAGA
GGAGTAAACGTGTCTGCTCTTAGCAGAGATATCAAATGGGACTTTACACCTTGCAAAAAC
CTACGGGTTGGTAGTCATATCACTGGCGGAGACATTTATGGAATTGTCAGTGAGAACTCG
CTTATCAAACACAAAATCATGTTACCCCCACGAAACAGAGGAACTGTAACTTACATTGCT
CCACCTGGGAATTATGATACCTCTGATGTTGTCTTGGAGCTTGAATTTGAAGGTGTAAAG
GAGAAGTTCACCATGGTGCAAGTATGGCCTGCACGTCAAGTTCGACCTGTCACTGAGAAG
CTGCCAGCCAATCATCCTCTGTTGACTGGCCAGAGAGTCCTTGATGCCCTTTTTCCGTGT
GTCCAGGGAGGAACTACTGCTATCCCTGGAGCCTTTGGCTGTGGAAAGACAGTGATATCA
CAGTCTCTATCCAAGTATTCTAACAGTGATGTAATCATCTATGTAGGATGTGGTGAAAGA
GGAAATGAGATGTCTGAAGTCCTCCGGGACTTCCCAGAGCTCACAATGGAGGTTGATGGT
AAGGTAGAGTCAATTATGAAGAGGACAGCTTTGGTAGCCAATACCTCCAATATGCCTGTT
GCTGCTAGAGAAGCCTCTATTTATACTGGAATCACACTGTCAGAGTACTTCCGTGACATG
GGCTATCATGTCAGTATGATGGCTGACTCTACCTCTAGATGGGCTGAGGCCCTTAGAGAA
ATCTCTGGTCGTTTAGCTGAAATGCCTGCAGATAGTGGATATCCAGCCTATCTTGGTGCC
CGTCTGGCCTCGTTTTATGAACGAGCAGGCAGGGTGAAATGTCTTGGAAATCCTGAAAGA
GAAGGGAGTGTCAGCATTGTAGGAGCAGTTTCTCCACCTGGTGGTGATTTTTCTGATCCA
GTTACATCTGCCACTCTTGGTATCGTTCAGGTGTTCTGGGGCTTAGATAAGAAACTAGCT
CAACGTAAGCATTTCCCCTCTGTCAATTGGCTCATCAGCTACAGCAAGTATATGCGTGCC
TTGGATGAATACTATGACAAACACTTCACAGAGTTCGTTCCTCTGAGGACGAAAGCTAAG
GAAATTCTGCAGGAAGAAGAAGACCTGGCAGAAATTGTACAGCTTGTGGGAAAGGCTTCT
TTGGCAGAAACAGATAAAATCACTCTGGAGGTAGCAAAACTTATCAAAGATGATTTCCTA
CAACAAAATGGATATACTCCTTATGACAGGTTCTGCCCATTCTACAAGACAGTAGGGATG
CTGTCCAACATGATTGCATTTTATGATATGGCTCGTAGAGCTGTTGAAACCACTGCCCAG
AGTGACAATAAAATCACATGGTCCATTATTCGTGAGCACATGGGAGACATCCTCTATAAA
CTTTCCTCCATGAAATTCAAGGATCCACTGAAAGATGGTGAGGCAAAGATCAAAAGCGAC
TATGCACAACTTCTTGAAGACATGCAGAATGCATTCCGTAGCCTTGAAGATTAG

# Drug_Target_3_General_Function:
Energy production and conversion

# Drug_Target_3_General_References:
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
8463241	van Hille B, Richener H, Evans DB, Green JR, Bilbe G: Identification of two subunit A isoforms of the vacuolar H(+)-ATPase in human osteoclastoma. J Biol Chem. 1993 Apr 5;268(10):7075-80.

# Drug_Target_3_HGNC_ID:
GNC:851

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
6057

# Drug_Target_3_Locus:
3q13.2-q13.31

# Drug_Target_3_Molecular_Weight:
68303.5

# Drug_Target_3_Name:
V-type proton ATPase catalytic subunit A

# Drug_Target_3_Number_of_Residues:
617

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00006	ATP-synt_ab
PF00306	ATP-synt_ab_C
PF02874	ATP-synt_ab_N

# Drug_Target_3_Protein_Sequence:
>V-type proton ATPase catalytic subunit A
MDFSKLPKILDEDKESTFGYVHGVSGPVVTACDMAGAAMYELVRVGHSELVGEIIRLEGD
MATIQVYEETSGVSVGDPVLRTGKPLSVELGPGIMGAIFDGIQRPLSDISSQTQSIYIPR
GVNVSALSRDIKWDFTPCKNLRVGSHITGGDIYGIVSENSLIKHKIMLPPRNRGTVTYIA
PPGNYDTSDVVLELEFEGVKEKFTMVQVWPVRQVRPVTEKLPANHPLLTGQRVLDALFPC
VQGGTTAIPGAFGCGKTVISQSLSKYSNSDVIIYVGCGERGNEMSEVLRDFPELTMEVDG
KVESIMKRTALVANTSNMPVAAREASIYTGITLSEYFRDMGYHVSMMADSTSRWAEALRE
ISGRLAEMPADSGYPAYLGARLASFYERAGRVKCLGNPEREGSVSIVGAVSPPGGDFSDP
VTSATLGIVQVFWGLDKKLAQRKHFPSVNWLISYSKYMRALDEYYDKHFTEFVPLRTKAK
EILQEEEDLAEIVQLVGKASLAETDKITLEVAKLIKDDFLQQNGYTPYDRFCPFYKTVGM
LSNMIAFYDMARRAVETTAQSDNKITWSIIREHMGDILYKLSSMKFKDPLKDGEAKIKSD
YAQLLEDMQNAFRSLED

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells

# Drug_Target_3_SwissProt_ID:
P38606

# Drug_Target_3_SwissProt_Name:
VATA_HUMAN

# Drug_Target_3_Synonyms:
V-ATPase 69 kDa subunit
V-ATPase subunit A
Vacuolar ATPase isoform VA68
Vacuolar proton pump subunit alpha

# Drug_Target_3_Theoretical_pI:
5.16

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB01077
